Keating Financial Advisory Services’s ARK Genomic Revolution ETF ARKG Stock Holding History

Keating Financial Advisory Services’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$557K	Sell	13,250 -329	-2%	-$10.5K	0.07%	188
2026 Q1	$359K	Sell	13,579 -2,364	-15%	-$69.2K	0.06%	233
2025 Q4	$462K	Buy	+15,943	New	+$479K	0.06%	227

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Keating Financial Advisory Services's ARKG Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its ARK Genomic Revolution ETF (ARKG) stake by 2.4% in Q2 2026, selling an estimated $10.5K and leaving 13,250 shares worth $557K. The position accounts for 0.07% of the portfolio, ranked #188.

Keating Financial Advisory Services first reported a position in ARKG in Q4 2025 and has held it in 3 quarters since. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Keating Financial Advisory Services held 13,250 shares of ARK Genomic Revolution ETF worth $557K as of Q2 2026.
Keating Financial Advisory Services sold 329 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $10.5K.
ARK Genomic Revolution ETF made up 0.07% of Keating Financial Advisory Services's portfolio in Q2 2026, its #188 holding.
Keating Financial Advisory Services first reported a position in ARK Genomic Revolution ETF in Q4 2025 and has held it in 3 quarters since.
271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.